Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.
Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.
What's Your Reaction?
